
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GFRα-1 CRISPR/Cas9 KO Plasmid (m) | sc-420539 | 20 µg | $397.00 |
Gfra1 encodes GFRα-1, a glycosylphosphatidylinositol-anchored co-receptor that binds glial cell line–derived neurotrophic factor (GDNF) and presents it to the RET tyrosine kinase to initiate downstream signaling. This ligand–receptor complex regulates neuronal survival, neurite outgrowth, and differentiation through pathways that include PI3K–AKT, MAPK/ERK, and PLCγ-dependent signaling, with additional roles in neural crest–derived tissues. In mouse, GFRα-1 activity is also implicated in kidney morphogenesis and the maintenance of spermatogonial stem cells, reflecting its broader function in developmental and tissue homeostasis programs. Dysregulation of GDNF–GFRα-1–RET signaling is widely used as a mechanistic framework for studying neurodevelopmental defects, neurodegeneration, and RET-driven cellular phenotypes in experimental models.
GFRα-1 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Gfra1 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Gfra1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Gfra1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GFRα-1 protein expression.
This CRISPR knockout system enables efficient generation of Gfra1-deficient cell models for investigation of GFRα-1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.